AZN.ST Earnings — AstraZeneca PLC

STO

Updated Oct 30, 2026

Price —

Market Cap $2.7T

P/E 25.5

52W Range — – —

When is AZN.ST's next earnings date?

AstraZeneca PLC (AZN.ST) has not announced its next earnings date yet. Its most recent earnings report was on Friday, October 30, 2026.

How did AZN.ST do in its last earnings report?

In its most recent report on Oct 30, 2026, AstraZeneca PLC posted EPS of $28.04 versus the $25.99 estimate, a beat of 7.9%. Revenue was $162.90B against a $160.83B estimate.

How much does AZN.ST stock move after earnings?

AZN.ST beat EPS estimates in 2 of its last 2 reported quarters.

About AstraZeneca PLC

AstraZeneca PLC functions as a global biopharmaceutical enterprise, dedicated to the entire lifecycle of prescription medicines, from initial discovery and development through manufacturing and commercialization. Its extensive product portfolio targets a broad spectrum of therapeutic areas. In oncology, key marketed treatments include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex. For cardiovascular, renal, and metabolism conditions, the company offers medicines such as Brilinta/Brilique, Bydureon/Byetta, BCise, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR. Respiratory and immunology products comprise Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris. Rare disease therapies feature Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris. Beyond these core categories, AstraZeneca also markets Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for influenza prevention; Seroquel IR/Seroquel XR for schizophrenia and bipolar disorder; gastrointestinal treatments Nexium and Losec/Prilosec; and COVID-19 related solutions Vaxzevria and Evusheld. AstraZeneca serves healthcare professionals in both primary and specialty care settings. It leverages a robust distribution network and local representative offices to reach markets across the United Kingdom, continental Europe, the Americas, Asia, Africa, and Australasia. The company frequently engages in strategic collaboration agreements to advance its pipeline. Notable partnerships include those with Regeneron Pharmaceuticals, Inc. for researching, developing, and commercializing small molecule medicines targeting obesity; Neurimmune AG for the development and commercialization of NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy currently in Phase III trials for transthyretin amyloidosis; Proteros Biostructures GmbH for joint discovery of novel small molecules aimed at hematological cancers; and Sierra Oncology, Inc. for the development and commercialization of AZD5153. Incorporated in 1992, the company initially operated as Zeneca Group PLC before adopting its current name, AstraZeneca PLC, in April 1999. Its corporate headquarters are situated in Cambridge, United Kingdom.

🤖 AI Earnings Analysis

AZN.ST’s reaffirmed “Buy” rating and insider purchase of 2,500 shares provide positive sentiment, while its 25.5× P/E leaves less room for execution missteps.

AI-generated summary — powered by BigEarnings.